[Translation] A randomized, open-label, single-dose, two-formulation, two-sequence, two-period crossover bioequivalence study of empagliflozin and metformin extended-release tablets in healthy study participants under fasting/fed conditions
主要目的:健康研究参与者空腹/餐后状态下,口服单剂量恩格列净二甲双胍缓释片(Metformin Hydrochloride And Empagliflozin Extended Release Tablets,受试制剂T,湖北午时药业股份有限公司生产,规格:25mg/1000mg/片)与恩格列净二甲双胍缓释片(Metformin Hydrochloride And Empagliflozin Extended Release Tablets,参比制剂R,Boehringer Ingelheim Pharmaceuticals,Inc生产,商品名:SYNJARDY XR®,规格:25mg/1000mg/片)进行生物等效研究,研究受试制剂与参比制剂在人体内的吸收速度和吸收程度,评价受试制剂与参比制剂是否具有生物等效性。
次要目的:观察受试制剂恩格列净二甲双胍缓释片和参比制剂恩格列净二甲双胍缓释片(SYNJARDY XR®)在健康研究参与者中的安全性。
[Translation] Main purpose: To conduct a bioequivalence study on healthy study participants taking a single oral dose of empagliflozin metformin extended release tablets (Metformin Hydrochloride And Empagliflozin Extended Release Tablets, test preparation T, produced by Hubei Wushi Pharmaceutical Co., Ltd., specification: 25mg/1000mg/tablet) and empagliflozin metformin extended release tablets (Metformin Hydrochloride And Empagliflozin Extended Release Tablets, reference preparation R, produced by Boehringer Ingelheim Pharmaceuticals, Inc., trade name: SYNJARDY XR®, specification: 25mg/1000mg/tablet) in the fasting/postprandial state, to study the absorption rate and degree of the test preparation and the reference preparation in the human body, and to evaluate whether the test preparation and the reference preparation are bioequivalent.
Secondary objective: To observe the safety of the test formulation, empagliflozin metformin extended-release tablets, and the reference formulation, empagliflozin metformin extended-release tablets (SYNJARDY XR®) in healthy study participants.